Shanghai MicroPort EV MedTech Co. Ltd. A

MicroPort EP released its 2026 interim report. The company's total operating revenue was 275 million yuan, and net profit attributable to the parent company was 40.0853 million yuan. Net cash inflow from operating activities was 1.2354 million yuan, down 98.08% from the same period last year. The company's asset-liability ratio was 10.93%, gross margin was 55.77%, ROE was 2.21%, and diluted earnings per share was 0.09 yuan. The number of shareholders was 13,500, and the top ten shareholders held 76.13% of the total share capital.

MicroPort EP released its 2026 interim report, showing attributable net profit of 40.09 million yuan in the first half, up 22.7% year on year. Operating revenue was 275 million yuan, up 23.02% year on year. Attributable net profit excluding non-recurring items was 3.16 million yuan, down 84.8% year on year. Net operating cash flow was 1.24 million yuan, down 98.1% year on year. In the second quarter, operating revenue was 149 million yuan, up 24.8% year on year, while attributable net profit was 11 million yuan, down 25.7% year on year. As of the end of the second quarter, total assets stood at 2.036 billion yuan, up 2.2% from the end of the previous year, and attributable net assets were 1.814 billion yuan, up 0.7% from the end of the previous year. The company said its electrophysiology interventional diagnosis and ablation treatment business continued to grow, with cumulative three-dimensional cardiac electrophysiology procedures exceeding 100,000 cases, covering more than 1,100 hospitals, and procedure volume for core products rising more than 45% compared with the same period last year.